Interim results interesting. There are numerous possibilities7 Sep 2023 08:32
For the Parsortix machine that can capture a live cancer cell from a sample of human blood for analysis. The sp here could rocket at any time. This part of the announcement caught my eye:-
"The use of circulating tumor DNA (ctDNA, fragments of dead cancer cells) testing for cancer patients is increasing not only in clinical trials but also in clinical centres. ANGLE has developed protocols for the Parsortix system where the same blood samples obtained for ctDNA testing can also be used for CTC DNA molecular analysis. Being intact living cancer cells, CTCs can provide additional DNA prospective insight not possible with ctDNA alone. Importantly, CTCs can also provide crucial RNA and protein information, which is not possible at all with ctDNA."
This could me marketed as the "Rolls-Royce" of information obtainable for analysis of cancer.
A tiny fraction of this market would see the sp rocket. A Pharma Co. who do molecular analysis could buy Angle and promote the machine and the associated analysis kits as the Rolls Royce of information available about a patients cancer.
Huge possibilities here.
Also Cash runway extended into Q1 2025.............
All IMHO.